Description
Enasinib, marketed under the brand name Enasidenib, It is an prescription medication that has been approved enasidenib (Idhifa) on August 1, 2017 for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Enasidenib is the first IDH2 inhibitor to be approved by the FDA.
What is (Enasidenib) ?
This medication is used to treat a certain type of blood cell cancer (acute myeloid leukemia-AML). Enasidenib works by helping your bone marrow grow normal blood cells so you will need fewer blood transfusions.
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2.
How to order approved ” (Enasidenib) for tablets” Medicine?
Enasidenib (Enasinib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing Enasidenib and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.





